Cargando…
Ixekizumab‐induced urticarial drug eruption
Biological agents targeting inflammatory skin diseases have dramatically overcome many of the limitations of older oral therapeutic options. Among the various biological agents, ixekizumab is a humanised monoclonal antibody that blocks the biological activity of IL‐17A, which exhibited high efficacy...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549868/ https://www.ncbi.nlm.nih.gov/pubmed/37799352 http://dx.doi.org/10.1002/ski2.271 |